James Spicer

King's College London — United Kingdom

Medicine · Health Sciences

66h-index15.4kcitations562works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(111), Cancer Immunotherapy and Biomarkers(68), Monoclonal and Polyclonal Antibodies Research(62), HER2/EGFR in Cancer Research(54), Cancer Research and Treatments(50)

Publications554 total

O19 Nonallergic urticarial skin reactions associated with MOv18 IgE, a first-in-class IgE antibody recognizing folate receptor alpha (FRα): linking allergooncology with dermatology
British Journal of Dermatology·2026
Abstract B041: Mitochondrial antioxidant peroxiredoxin 3 is a tractable therapeutic target in mesothelioma
Molecular Cancer Therapeutics·2025
P3.18.29 NAPISTAR 1-01: An International Phase I/II Trial of the Novel ADC TUB-040 in Advanced/Metastatic NSCLC Adenocarcinoma
Journal of Thoracic Oncology·2025
LBA106 3D-response and multiomic correlates of niraparib in relapsed mesothelioma: NERO, a randomised clinical trial in patients with relapsed mesothelioma
Annals of Oncology·2025
WITHDRAWN: 1005eP Toxicity of tumour infiltrating lymphocyte (TIL) therapy in solid tumours: Experience from a UK trials unit
Annals of Oncology·2025
1557P IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) treatment of advanced solid tumors: Final results of a phase II basket trial
Annals of Oncology·2025
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study
Cancers·2025· 3 citedOpen Access
An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer
Science Translational Medicine·2025· 4 citedOpen Access
AllergoOncology: Non-Allergic Urticarial Skin Reactions Associated with MOv18 IgE, a First-in-Class IgE Antibody Recognising FRα
EMJ Allergy & Immunology·2025Open Access
Tumor microenvironments with an active type I IFN response are sensitive to inhibitors of heme degradation
JCI Insight·2025· 1 citedOpen Access
NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2025· 1 cited
A phase Ib, open-label trial of MOv18 IgE in patients with advanced ovarian cancer.
Journal of Clinical Oncology·2025
Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stability
mAbs·2025· 3 citedOpen Access
Corrigendum to ‘A Phase Ib, Open-Label Trial Of MOv18 IgE In Patients With Advanced Ovarian Cancer’ [International Journal of Gynecological Cancer Volume 35, Issue 2 Supplement 1 (2025) #809]
International Journal of Gynecological Cancer·2025Open Access
Abstract CT058: Final results of a first-in-human (FIH) study of intratumoral pan-ErbB-targeted CAR-T cell therapy for head and neck squamous cell carcinoma (HNSCC): T4 immunotherapy
Cancer Research·2025· 1 cited
Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction
Nature Communications·2025· 10 citedOpen Access
PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer
British Journal of Cancer·2025· 2 citedOpen Access
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
npj Precision Oncology·2025· 3 citedOpen Access
Non‐Allergic Urticarial Skin Reactions Associated With <scp>MOv18 IgE</scp> , a First‐In‐Class <scp>IgE</scp> Antibody Recognising Folate Receptor Alpha
Allergy·2025· 3 citedOpen Access
419P: Predictors and outcomes of non-small cell lung carcinoma (NSCLC) patients following severe immune checkpoint inhibitor (ICI) toxicity: A real-world UK multi-centre study
Journal of Thoracic Oncology·2025Open Access
page 1 of 28Next →

Frequent Co-authors

Sophia N. Karagiannis(15), Debra H. Josephs(12), Sophie Papa(9), Anthony Cheung(8), Katie E. Lacy(8), Silvia Crescioli(7), Heather J. Bax(6), Kristina M. Ilieva(6), Loı̈c Lang-Lazdunski(5), Mark Harries(5), Andrew Tutt(5), Silvia Mele(5), Ricarda M. Hoffmann(5), Panagiotis Karagiannis(5), Frank O. Nestlé(5), David Landau(4), Giulia Pellizzari(4), Johann S. de Bono(4), Mano Nakamura(4), Jenny L. C. Geh(4)